PL365787A1 - Związki heterocykliczne, ich wytwarzanie i zastosowanie - Google Patents

Związki heterocykliczne, ich wytwarzanie i zastosowanie

Info

Publication number
PL365787A1
PL365787A1 PL01365787A PL36578701A PL365787A1 PL 365787 A1 PL365787 A1 PL 365787A1 PL 01365787 A PL01365787 A PL 01365787A PL 36578701 A PL36578701 A PL 36578701A PL 365787 A1 PL365787 A1 PL 365787A1
Authority
PL
Poland
Prior art keywords
production
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
PL01365787A
Other languages
English (en)
Inventor
Akihiro Tasaka
Takenori Hitaka
Etsuya Matsutani
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of PL365787A1 publication Critical patent/PL365787A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL01365787A 2000-04-07 2001-04-05 Związki heterocykliczne, ich wytwarzanie i zastosowanie PL365787A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000106836 2000-04-07
PCT/JP2001/002937 WO2001077107A1 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
PL365787A1 true PL365787A1 (pl) 2005-01-10

Family

ID=18619943

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365787A PL365787A1 (pl) 2000-04-07 2001-04-05 Związki heterocykliczne, ich wytwarzanie i zastosowanie

Country Status (19)

Country Link
US (2) US6716863B2 (pl)
EP (1) EP1268473A1 (pl)
KR (1) KR20020028865A (pl)
CN (1) CN1444582A (pl)
AU (1) AU2001244726A1 (pl)
BR (1) BR0109851A (pl)
CA (1) CA2404760A1 (pl)
CO (1) CO5261589A1 (pl)
CZ (1) CZ20023264A3 (pl)
EE (1) EE200200576A (pl)
HU (1) HUP0300434A3 (pl)
IL (1) IL152115A0 (pl)
MX (1) MXPA02009621A (pl)
NO (1) NO20024742L (pl)
OA (1) OA12244A (pl)
PE (1) PE20011178A1 (pl)
PL (1) PL365787A1 (pl)
SK (1) SK14132002A3 (pl)
WO (1) WO2001077107A1 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136079A4 (en) * 1998-10-08 2004-09-22 Takeda Chemical Industries Ltd AGENTS FOR DELAYING THE TRANSFER FROM HORMONO-DEPENDENT CANCER TO HORMONO-INDEPENDENT CANCER
EP1310491A1 (en) * 2000-07-19 2003-05-14 Takeda Chemical Industries, Ltd. Method for producing 1-substituted-1,2,3-triazole derivative
US20040235748A1 (en) * 2001-04-25 2004-11-25 Yasutaka Igari Agents for preventing postoperative recurrence of premenopausal breast cancer
WO2002087618A1 (en) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US20040138160A1 (en) * 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
WO2003015820A1 (en) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. GnRH AGONIST COMBINATION DRUGS
EP1439178A4 (en) * 2001-10-05 2005-11-16 Takeda Pharmaceutical Heterocyclic compounds, oxazole derivatives, process for their preparation and their use
EP1444988A4 (en) 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
WO2003045929A1 (en) * 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
AU2003203170A1 (en) * 2002-01-17 2003-07-30 Takeda Chemical Industries, Ltd. Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US20060018959A1 (en) * 2002-12-16 2006-01-26 Kissei Pharmaceutical Co. Ltd. Solid drug for oral use
TW200505913A (en) * 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200423931A (en) * 2003-04-30 2004-11-16 Hoffmann La Roche Novel aniline derivatives, their manufacture and use as pharmaceutical agents
US7247649B2 (en) * 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200612914A (en) * 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200533346A (en) 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
WO2005097777A1 (en) 2004-04-02 2005-10-20 F. Hoffmann-La-Roche Ag New process for the preparation of diazine derivatives
US7005526B2 (en) * 2004-05-25 2006-02-28 Hoffmann-La Roche Inc. Thioether derivatives
US7163953B2 (en) * 2004-05-25 2007-01-16 Hoffmann-La Roche Inc. Benzylether derivatives
US7618769B2 (en) * 2004-06-07 2009-11-17 Applied Materials, Inc. Textured chamber surface
US7288557B2 (en) 2004-09-21 2007-10-30 Hoffmann-La Roche Inc. Triazole derivatives
US7342030B2 (en) 2004-09-22 2008-03-11 Hoffmann-La Roche Inc. Indole derivatives
TW200626589A (en) * 2004-09-24 2006-08-01 Hoffmann La Roche Azole derivatives, their manufacture and use as pharmaceutical agents
US20060116407A1 (en) * 2004-11-22 2006-06-01 Birgit Bossenmaier Amide derivatives
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
US7429605B2 (en) * 2005-08-04 2008-09-30 Hoffmann-La Roche Inc. Phenylpyridine derivatives
US20090264485A1 (en) * 2005-08-08 2009-10-22 Hans-Willi Krell Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents
US20090093491A1 (en) * 2005-09-30 2009-04-09 Wolfgang Jenni Diazine Azole Derivatives, Their Manufacture and Use as Pharmaceutical
WO2008034579A1 (en) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 2-heterocyclyl-5-phenoxymethylpyridine derivatives as anticancer agents
KR20090090336A (ko) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
CN101657216B (zh) 2007-04-20 2012-11-21 大同化成工业株式会社 干式固体分散体用基剂、含有该基剂的固体分散体及含有该分散体的组合物
JPWO2009113560A1 (ja) 2008-03-12 2011-07-21 武田薬品工業株式会社 縮合複素環化合物
AR073680A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la mutacion del gen ras. composicion farmaceutica. uso.
WO2010036928A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation)
KR101442069B1 (ko) 2009-09-30 2014-09-18 가부시키가이샤 상기 난용성 물질의 수용해성 개선방법
JP5705206B2 (ja) 2010-02-26 2015-04-22 日新化成株式会社 硬カプセルおよびその製造方法
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
WO2014050910A1 (ja) 2012-09-26 2014-04-03 武田薬品工業株式会社 固体粒子の製造方法
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems
EP3238711B1 (en) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base for solid dispersion, production method for solid dispersion using same, and solid dispersion
CA2995617A1 (en) * 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CN114217025B (zh) * 2021-12-17 2024-01-23 哈尔滨工业大学 评估空气质量浓度预测中气象数据对其影响的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525109A4 (en) 1990-04-16 1993-06-30 Rhone-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
AU3461697A (en) * 1996-07-19 1998-02-10 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
HUP0300434A3 (en) 2004-11-29
SK14132002A3 (sk) 2003-04-01
OA12244A (en) 2006-05-10
CO5261589A1 (es) 2003-03-31
EP1268473A1 (en) 2003-01-02
US6716863B2 (en) 2004-04-06
HUP0300434A2 (hu) 2003-06-28
WO2001077107A1 (en) 2001-10-18
NO20024742D0 (no) 2002-10-02
PE20011178A1 (es) 2001-11-19
EE200200576A (et) 2004-06-15
AU2001244726A1 (en) 2001-10-23
BR0109851A (pt) 2003-06-03
KR20020028865A (ko) 2002-04-17
US20020173526A1 (en) 2002-11-21
WO2001077107B1 (en) 2001-12-20
WO2001077107A8 (en) 2003-02-13
CZ20023264A3 (cs) 2003-02-12
NO20024742L (no) 2002-11-25
IL152115A0 (en) 2003-05-29
US20040024035A1 (en) 2004-02-05
CA2404760A1 (en) 2001-10-18
CN1444582A (zh) 2003-09-24
MXPA02009621A (es) 2003-05-14

Similar Documents

Publication Publication Date Title
HUP0104917A3 (en) Azepinoindole derivatives, the production and use thereof
EG22695A (en) Novel phenyl-propargylether derivatives
IL145549A (en) Thienopyrimidine compounds, their production and use
IL148419A0 (en) Benzodiazepine derivatives, the production and use thereof
GB2361235B (en) 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides
ZA200206198B (en) New aza-indolyl derivatives.
AU9684401A (en) Hedgehog antagonists, methods and uses related thereto
AU6053701A (en) 2-aminocarbonyl-9h-purine derivatives
PL359666A1 (pl) Heterocykliczne acylosulfimidy, sposób ich wytwarzania, zawierające je środki i ich zastosowanie jako środków szkodnikobójczych
IL155624A0 (en) Novel imidazole derivatives, production method thereof and use thereof
IL136950A0 (en) Heterocyclic compounds, their production and use
GB0007333D0 (en) Novel compounds and their manufacture and use
AU5884101A (en) Heterocyclic compounds
HUP0302065A3 (en) Chromanone derivatives, production and use thereof
AU2001244608A1 (en) Fused heterocyclic derivatives, their production and use
HUP0300222A3 (en) Novel lhrh-antagonists, production and use thereof as medicament
IL151082A0 (en) Thienopyridine derivatives, their production and use
HUP0300306A3 (en) Cyclipostins, a method for their production and the use of the same
ZA200206140B (en) Heterocyclic amide Derivatives.
HU0001397D0 (en) 3-amino-3-arylpropan-1-ol derivatives, production and use thereof
AU7815201A (en) Synthetic salicylihalamides, apicularens and derivatives thereof
IL157793A0 (en) Caloporoside derivatives, methods for the production thereof and their use
GB0000430D0 (en) Tametip
AU2795202A (en) Klainetin and derivatives thereof, method for their production and the use of the same
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)